• FDA cleared Thiogenesis Therapeutics' investigational new drug application for TTI-0102 in nephropathic cystinosis on October 16, 2026.
• The pilot study will evaluate once-daily treatment in approximately six adults for seven days.
• Topline data are expected in the first quarter of 2027, assuming timely study initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thiogenesis Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610220500NEWSFILECNPR____20261022_320172_1) on October 22, 2026, and is solely responsible for the information contained therein.